MacroGenics' Tebotelimab Study Meets Primary Endpoint
Ticker: MGNX · Form: 8-K · Filed: 2026-04-08T16:41:59-04:00
Sentiment: bullish
Topics: clinical-trial-results, oncology, partnership
Related Tickers: MRK
TL;DR
MGNX tebotelimab + Keytruda combo CRUSHED Phase 2 LINGO-2 study for urothelial carcinoma, met PFS endpoint!
AI Summary
On April 8, 2026, MacroGenics Inc. filed an 8-K report detailing the results of the Phase 2 LINGO-2 study for its drug tebotelimab. The study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) for patients with advanced or metastatic urothelial carcinoma who received tebotelimab in combination with Merck's Keytruda compared to those receiving Keytruda alone.
Why It Matters
This positive outcome in the LINGO-2 study is a significant step for MacroGenics, potentially paving the way for broader regulatory approval and commercialization of tebotelimab in a key cancer indication.
Risk Assessment
Risk Level: medium — While the study met its primary endpoint, further clinical trials and regulatory review are necessary, and commercial success is not guaranteed.
Key Numbers
- Phase 2 — Study Phase (Indicates the stage of clinical development for tebotelimab in this study.)
Key Players & Entities
- MacroGenics Inc. (company) — Filer of the 8-K report and developer of tebotelimab
- tebotelimab (drug) — Drug developed by MacroGenics, tested in the LINGO-2 study
- LINGO-2 study (study) — Phase 2 clinical trial for tebotelimab
- Merck (company) — Manufacturer of Keytruda, used in combination therapy
- Keytruda (drug) — Drug manufactured by Merck, used in combination with tebotelimab
- advanced or metastatic urothelial carcinoma (disease) — Cancer type studied in the LINGO-2 trial
- April 8, 2026 (date) — Filing date of the 8-K report
FAQ
What was the primary endpoint of the LINGO-2 study?
The primary endpoint was progression-free survival (PFS).
What was the combination therapy tested in the LINGO-2 study?
The combination therapy was tebotelimab with Merck's Keytruda.
What was the comparator arm in the LINGO-2 study?
The comparator arm received Keytruda alone.
What type of cancer was targeted in the LINGO-2 study?
The study targeted patients with advanced or metastatic urothelial carcinoma.
When was this 8-K filing made?
The 8-K filing was made on April 8, 2026.
From the Filing
EDGAR Filing Documents for 0001125345-26-000026 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001125345-26-000026 Filing Date 2026-04-08 Accepted 2026-04-08 16:41:59 Documents 13 Period of Report 2026-04-08 Items Item 8.01: Other Events Interactive Data Document Format Files Seq Description Document Type Size 1 8-K mgnx-20260408.htm iXBRL 8-K 29604 2 EX-99.1 exhibit991_linnetstudyhold.htm EX-99.1 14302 6 MACROGENICS LOGO macrogenics20logo_jpgormat.jpg GRAPHIC 139164 Complete submission text file 0001125345-26-000026.txt 354139 Data Files Seq Description Document Type Size 3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mgnx-20260408.xsd EX-101.SCH 1782 4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mgnx-20260408_lab.xml EX-101.LAB 21629 5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mgnx-20260408_pre.xml EX-101.PRE 12508 16 EXTRACTED XBRL INSTANCE DOCUMENT mgnx-20260408_htm.xml XML 2717 Mailing Address 9704 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 Business Address 9704 MEDICAL CENTER DRIVE Rockville MD 20850 301-251-5172 MACROGENICS INC (Filer) CIK : 0001125345 (see all company filings) EIN. : 000000000 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-36112 | Film No.: 26848644 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)